Zenas Biopharma, Common Etf Price on September 25, 2024

ZBIO Etf  USD 11.51  0.24  2.04%   
If you're considering investing in Zenas Etf, it is important to understand the factors that can impact its price. As of today, the current price of Zenas BioPharma, stands at 11.51, as last reported on the 1st of December, with the highest price reaching 11.87 and the lowest price hitting 11.42 during the day. Zenas BioPharma, Common shows Sharpe Ratio of -0.11, which attests that the etf had a -0.11% return per unit of risk over the last 3 months. Zenas BioPharma, Common exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Zenas BioPharma,'s Market Risk Adjusted Performance of (1.86), mean deviation of 4.3, and Standard Deviation of 6.0 to validate the risk estimate we provide.
  
Zenas Etf price history is provided at the adjusted basis, taking into account all of the recent filings.

Sharpe Ratio = -0.1065

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsZBIO

Estimated Market Risk

 5.95
  actual daily
52
52% of assets are less volatile

Expected Return

 -0.63
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.11
  actual daily
0
Most of other assets perform better
Based on monthly moving average Zenas BioPharma, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zenas BioPharma, by adding Zenas BioPharma, to a well-diversified portfolio.

Related Headline

Enveric Biosciences Headline on 25th of September 2024

Psychedelics biotech company Enveric Biosciences has presented research highlighting the companys lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being held at the Hilton Boston Back Bay in Boston, Massachusetts on Sept. 24-26, 2024. EB-003 is a neuropathogenic and non-hallucinogenic N, N-Dimethyltryptamine analog drug candidate that showed beneficial outcomes in preclinical models of anxiety and depression. The move follows the companys July announcement of positive pre-clinical results of its EB-003 drug candidate to be delivered via oral administration. The results indicated that oral administration of EB-003 provides significant brain exposure in rodent models at potential therapeutic doses.

Zenas BioPharma, Valuation on September 25, 2024

It is possible to determine the worth of Zenas BioPharma, on a given historical date. On September 25, 2024 Zenas was worth 19.63 at the beginning of the trading date compared to the closed value of 18.42. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Zenas BioPharma, etf. Still, in general, we apply an absolute valuation method to find Zenas BioPharma,'s value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Zenas BioPharma, where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Zenas BioPharma,'s related companies.
 Open High Low Close Volume
  18.89    19.80    18.44    19.23    70,900  
09/25/2024
  19.63    20.50    18.06    18.42    125,900  
  18.70    19.50    16.50    17.29    164,828  
Backtest Zenas BioPharma,  |  Zenas BioPharma, History  |  Zenas BioPharma, Valuation   PreviousNext  
Open Value
19.63
18.42
Closing Value
37.48
Upside

Zenas BioPharma, Trading Date Momentum on September 25, 2024

On September 26 2024 Zenas BioPharma, Common was traded for  17.29  at the closing time. The top price for the day was 19.50  and the lowest listed price was  16.50 . The trading volume for the day was 164.8 K. The trading history from September 26, 2024 was a factor to the next trading day price decrease. The trading date delta against the next closing price was 6.13% . The trading date delta against the current closing price is 1.47% .

Zenas BioPharma, Common Fundamentals Correlations and Trends

By evaluating Zenas BioPharma,'s financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Zenas BioPharma,'s main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Zenas financial account trend analysis is a perfect complement when working with valuation or volatility modules.

About Zenas BioPharma, Etf history

Zenas BioPharma, investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Zenas is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Zenas BioPharma, Common will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Zenas BioPharma, stock prices may prove useful in developing a viable investing in Zenas BioPharma,
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States.

Zenas BioPharma, Quarterly Net Working Capital

149.49 Million

Zenas BioPharma, Etf Technical Analysis

Zenas BioPharma, technical etf analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, etf market cycles, or different charting patterns.
A focus of Zenas BioPharma, technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Zenas BioPharma, trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Price Boundaries

Zenas BioPharma, Period Price Range

Low
December 1, 2024
0.00  NaN%
High

 0.00 

     

 0.00 

Zenas BioPharma, Common cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.

Zenas BioPharma, December 1, 2024 Market Strength

Market strength indicators help investors to evaluate how Zenas BioPharma, etf reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Zenas BioPharma, shares will generate the highest return on investment. By undertsting and applying Zenas BioPharma, etf market strength indicators, traders can identify Zenas BioPharma, Common entry and exit signals to maximize returns

Zenas BioPharma, Technical and Predictive Indicators

Predictive indicators are helping investors to find signals for Zenas BioPharma,'s price direction in advance. Along with the technical and fundamental analysis of Zenas Etf historical price patterns, it is also worthwhile for investors to track various predictive indicators of Zenas to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.

Other Information on Investing in Zenas Etf

Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.